Protein C Inhibitor as a Diagnostic Marker: Immunohistochemical Expression in Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

ORIGINAL ARTICLE
Liridon Selmani, Rinё Limani, Riaz Agahi, Ilir Hoxha, Suzana Manxhuka Kёrliu

 
For citation: Selmani L, Limani R, Agahi R, Hoxha I, Kёrliu SM. Protein C Inhibitor as a Diagnostic Marker: Immunohistochemical Expression in Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia. International Journal of Biomedicine. 2024;14(3):441-447. doi:10.21103/Article14(3)_OA8
 
Originally published September 6, 2024

Abstract: 

Background: This study explores the immunohistochemical expression of protein C inhibitor (PCI) in patients with prostatic adenocarcinoma (PCa) and benign prostatic hyperplasia (BPH).
Methods and Results: Our study involved 56 prostate samples morphologically diagnosed as PCa and 30 BPH samples. An immunohistochemical analysis of the PCI expression was performed. Our analysis encompassed variables including age, serum prostate-specific antigen (PSA), local and distant metastasis, PCI staining, and morphological features such as Gleason Score and Grade Group. In addition to descriptive statistics, Spearman's rank correlation test was performed. All patients with BPH had no staining or low staining for PCI. 60% of PCa patients had moderate or strong staining intensity for PCI. There was no correlation between PCI expression and clinicopathological parameters, including PCI expression and PSA, Gleason Score, and Grade Group. A negative correlation was observed between age at diagnosis and PCI expression.
Conclusion: Our study did not find a statistically significant correlation between PCI and PCa. However, we report that in 60% of our PCa cases, there is a moderate and high-intensity expression for PCI.

Keywords: 
prostate • cancer • biomarkers • protein C inhibitor
References: 
  1. Okpua NC, Okekpa SI, Njaka S, Emeh AN. Clinical diagnosis of prostate cancer using digital rectal examination and prostate-specific antigen tests: a systematic review and meta-analysis of sensitivity and specificity. Afr J Urol. 2021;27(1):32.  doi: 10.1186/s12301-021-00129-x.
  2. Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26. PMID: 30824296; PMCID: PMC7513694.
  3. Zadnik V, Zagar T, Lokar K, Tomsic S, Konjevic AD, Zakotnik B. Trends in population-based cancer survival in Slovenia. Radiol Oncol. 2021 Jan 21;55(1):42-49. doi: 10.2478/raon-2021-0003. PMID: 33885247; PMCID: PMC7877261.
  4. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31. PMID: 25556937.
  5. Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health. 2022 Feb 16;10:811044. doi: 10.3389/fpubh.2022.811044. PMID: 35252092; PMCID: PMC8888523.
  6. Agahi R, Veselaj F, Islami DA, Selmani E, Khan O, Hoxha I. Impact of Prostate Cancer in Eastern Europe and Approaches to Treatment and Policy. Hematol Oncol Clin North Am. 2024 Feb;38(1):87-103. doi: 10.1016/j.hoc.2023.06.007. Epub 2023 Jul 27. PMID: 37516633.
  7. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18. PMID: 19297566.
  8. Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, Bawor M, Banfield L, Profetto J. Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. Ann Fam Med. 2018 Mar;16(2):149-154. doi: 10.1370/afm.2205. PMID: 29531107; PMCID: PMC5847354.
  9. Schröder FH. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening. N Engl J Med. 2011 Nov 24;365(21):1953-5. doi: 10.1056/NEJMp1112140. Epub 2011 Oct 26. PMID: 22029756.
  10. Liu Y, Hegde P, Zhang F, Hampton G, Jia S. Prostate cancer - a biomarker perspective. Front Endocrinol (Lausanne). 2012 May 29;3:72. doi: 10.3389/fendo.2012.00072. PMID: 22661971; PMCID: PMC3361745.
  11. Limani R, Lež C, Krušlin B. Exploring the Relationship between E-Cadherin and β-Catenin Cell Adhesion Proteins and Periacinar Retraction Clefting in Prostatic Adenocarcinoma. Diagnostics (Basel). 2024 Feb 28;14(5):511. doi: 10.3390/diagnostics14050511. PMID: 38472982; PMCID: PMC10930913.
  12. Locke JA, Black PC. Next generation biomarkers in prostate cancer. Front Biosci (Landmark Ed). 2016 Jan 1;21(2):328-42. doi: 10.2741/4391. PMID: 26709776.
  13. Suzuki K. Protein C Inhibitor (PAI-3): Structure and Multi-Function. Fibrinolysis Proteolysis. 2000;14(2):133-145. doi: 10.1054/fipr.2000.0063.
  14. Glasscock LN, Réhault SM, Gregory CW, Cooper ST, Jackson TP, Hoffman M, Church FC. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. Exp Mol Pathol. 2005 Aug;79(1):23-32. doi: 10.1016/j.yexmp.2005.02.008. PMID: 15878512.
  15. Rosenzweig CN, Zhang Z, Sun X, Sokoll LJ, Osborne K, Partin AW, Chan DW. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009 Mar;181(3):1407-14. doi: 10.1016/j.juro.2008.10.142. Epub 2009 Jan 20. PMID: 19157448; PMCID: PMC4130150.
  16. Cao Y, Becker C, Lundwall A, Christensson A, Gadaleanu V, Lilja H, Bjartell A. Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. Prostate. 2003 Nov 1;57(3):196-204. doi: 10.1002/pros.10296. PMID: 14518028.
  17. Bijsmans IT, Smits KM, de Graeff P, Wisman GB, van der Zee AG, Slangen BF, de Bruïne AP, van Engeland M, Sieben NL, Van de Vijver KK. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors. Mod Pathol. 2011 Mar;24(3):463-70. doi: 10.1038/modpathol.2010.214. Epub 2010 Nov 19. PMID: 21102419.
  18. Zhang Z, Chan DW, Rosenzwelg CN. Protein C Inhibitor as a Biomarker for Prostate Cancer. US8440409B2, May 14, 2013.  https://patents.google.com/patent/US8440409B2/en (accessed 2023-12-17).
  19. Lee S, Chintalapudi K, Badu-Tawiah AK. Clinical Chemistry for Developing Countries: Mass Spectrometry. Annu Rev Anal Chem (Palo Alto Calif). 2021 Jul 27;14(1):437-465. doi: 10.1146/annurev-anchem-091520-085936. PMID: 33979544; PMCID: PMC8932337.
  20. Merriel SWD, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, Hamilton W. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022 Feb 7;20(1):54. doi: 10.1186/s12916-021-02230-y. PMID: 35125113; PMCID: PMC8819971.
  21. Cinislioglu AE, Demirdogen SO, Cinislioglu N, Altay MS, Sam E, Akkas F, Tor IH, Aydin HR, Karabulut I, Ozbey I. Variation of Serum PSA Levels in COVID-19 Infected Male Patients with Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys. Urology. 2022 Jan;159:16-21. doi: 10.1016/j.urology.2021.09.016. Epub 2021 Oct 6. PMID: 34626600; PMCID: PMC8493783.
  22. Bai X, Jiang Y, Zhang X, Wang M, Tian J, Mu L, Du Y. The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer. Cancer Manag Res. 2020 Aug 4;12:6821-6826. doi: 10.2147/CMAR.S257769. PMID: 32801907; PMCID: PMC7414922.
  23. Razavi M, Johnson LD, Lum JJ, Kruppa G, Anderson NL, Pearson TW. Quantification of a proteotypic peptide from protein C inhibitor by liquid chromatography-free SISCAPA-MALDI mass spectrometry: application to identification of recurrence of prostate cancer. Clin Chem. 2013 Oct;59(10):1514-22. doi: 10.1373/clinchem.2012.199786. Epub 2013 Jul 15. PMID: 23857672.
  24. Harish BS, Uppuluri KB, Chapter 8 - Serine Proteases Leading to Prostate Cancer: Structures, Functions, and Development of Anticancer Drugs. In: Gupta SP, editor. Cancer-Leading Proteases. Academic Press; 2020:215-242.  https://doi.org/10.1016/B978-0-12-818168-3.00008-5.
  25. Grover SP, Mackman N. Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis. Front Cardiovasc Med. 2022 May 3;9:878199. doi: 10.3389/fcvm.2022.878199. PMID: 35592395; PMCID: PMC9110684.
  26. Siddiqui U, Khan AB, Ahmad T, Rehman AA, Jairajpuri MA. A common protein C inhibitor exosite partially controls the heparin induced activation and inhibition of serine proteases. Int J Biol Macromol. 2024 May;266(Pt 2):131065. doi: 10.1016/j.ijbiomac.2024.131065. Epub 2024 Mar 21. PMID: 38521329.
  27. España F, Estellés A, Fernández PJ, Gilabert J, Sánchez-Cuenca J, Griffin JH. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma. Thromb Haemost. 1993 Dec 20;70(6):989-94. PMID: 8165623.
  28. Wilts IT, Hutten BA, Meijers JCM, Spek CA, Büller HR, Kamphuisen PW. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer. Thromb Res. 2017 Jun;154:1-6. doi: 10.1016/j.thromres.2017.03.001. Epub 2017 Mar 7. PMID: 28376316.
  29. Suzuki K, Hayashi T. Protein C and its inhibitor in malignancy. Semin Thromb Hemost. 2007 Oct;33(7):667-72. doi: 10.1055/s-2007-991534. PMID: 18000793.
  30. Zheng D, Chen H, Davids J, Bryant M, Lucas A. Serpins for diagnosis and therapy in cancer. Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):123-32. doi: 10.2174/1871529x11313020005. PMID: 23988000.
  31. Geiger M, Huber K, Wojta J, Stingl L, Espana F, Griffin JH, Binder BR. Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo. Blood. 1989 Aug 1;74(2):722-8. PMID: 2752144.
  32. Elisen MG, von dem Borne PA, Bouma BN, Meijers JC. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood. 1998 Mar 1;91(5):1542-7. Erratum in: Blood 1998 Apr 15;91(8):3091. PMID: 9473218.
  33. Wakita T, Hayashi T, Nishioka J, Tamaru H, Akita N, Asanuma K, Kamada H, Gabazza EC, Ido M, Kawamura J, Suzuki K. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma. Int J Cancer. 2004 Feb 10;108(4):516-23. doi: 10.1002/ijc.11594. PMID: 14696115.
  34. Fan M, Xiong X, Han L, Zhang L, Gao S, Liu L, Wang X, Huang C, Tong D, Yang J, Zhao L, Shao Y. SERPINA5 promotes tumour cell proliferation by modulating the PI3K/AKT/mTOR signalling pathway in gastric cancer. J Cell Mol Med. 2022 Sep;26(18):4837-4846. doi: 10.1111/jcmm.17514. Epub 2022 Aug 24. PMID: 36000536; PMCID: PMC9465189.
  35. Wan J, Vadaq N, Konings J, Jaeger M, Kumar V, de Laat B, Joosten L, Netea MG, van der Ven AJ, de Groot PG, de Mast Q, Roest M. Kallikrein augments the anticoagulant function of the protein C system in thrombin generation. J Thromb Haemost. 2022 Jan;20(1):48-57. doi: 10.1111/jth.15530. Epub 2021 Sep 28. PMID: 34532976; PMCID: PMC9293419.
  36. Do Carmo Silva J, Vesely S, Luksanova H, Prusa R, Babjuk M. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2. Tumour Biol. 2021;43(1):197-207. doi: 10.3233/TUB-211509. PMID: 34486998.
  37. Kimura S, D'Andrea D, Iwata T, Foerster B, Janisch F, Parizi MK, Moschini M, Briganti A, Babjuk M, Chlosta P, Karakiewicz PI, Enikeev D, Rapoport LM, Seebacher V, Egawa S, Abufaraj M, Shariat SF. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. World J Urol. 2020 Oct;38(10):2501-2511. doi: 10.1007/s00345-019-03038-5. Epub 2019 Dec 4. PMID: 31797075.
  38. Seregni E, Botti C, Ballabio G, Bombardieri E. Biochemical characteristics and recent biological knowledge on prostate-specific antigen. Tumori. 1996 Jan-Feb;82(1):72-7. doi: 10.1177/030089169608200116. PMID: 8623511.
  39. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res. 2008 Sep 1;68(17):7110-9. doi: 10.1158/0008-5472.CAN-07-6507. PMID: 18757426; PMCID: PMC2587124.
  40. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. PMID: 33172724.
  41. Muazzam A, Spick M, Cexus ONF, Geary B, Azhar F, Pandha H, Michael A, Reed R, Lennon S, Gethings LA, Plumb RS, Whetton AD, Geifman N, Townsend PA. A Novel Blood Proteomic Signature for Prostate Cancer. Cancers (Basel). 2023 Feb 7;15(4):1051. doi: 10.3390/cancers15041051. PMID: 36831393; PMCID: PMC9954127.
  42. Wan Z, Zuo X, Wang S, Zhou L, Wen X, Yao Y, Song J, Gu J, Wang Z, Liu R, Luo C. Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma. Cancer Med. 2023 Aug;12(16):17445-17467. doi: 10.1002/cam4.6316. Epub 2023 Jul 11. PMID: 37434432; PMCID: PMC10501277.
  43. Hagelgans A, Jandeck C, Friedemann M, Donchin A, Richter S, Menschikowski M. Identification of CpG Sites of SERPINA5 Promoter with Opposite Methylation Patterns in Benign and Malignant Prostate Cells. Anticancer Res. 2017 Dec;37(12):6609-6618. doi: 10.21873/anticanres.12118. PMID: 29187436.

Download Article
Received June 12, 2024.
Accepted July 28, 2024.
©2024 International Medical Research and Development Corporation.